Biodesix, Inc. (BDSX) Bundle
Understanding Biodesix, Inc. (BDSX) Revenue Streams
Understanding Biodesix, Inc.’s Revenue Streams
Biodesix, Inc. generates revenue primarily through two sources: diagnostic testing and biopharmaceutical services. The following is a detailed analysis of their revenue streams as of 2024.
Breakdown of Primary Revenue Sources
-
Diagnostic Testing Revenue:
- Three Months Ended September 30, 2024: $17.2 million (40% increase from $12.3 million in 2023)
- Nine Months Ended September 30, 2024: $47.5 million (47% increase from $32.4 million in 2023)
-
Biopharmaceutical Services Revenue:
- Three Months Ended September 30, 2024: $1.0 million (17% decrease from $1.2 million in 2023)
- Nine Months Ended September 30, 2024: $3.4 million (68% increase from $2.0 million in 2023)
Year-over-Year Revenue Growth Rate
The overall revenue for Biodesix increased significantly in 2024:
| Period | Total Revenue | Year-over-Year Change |
|---|---|---|
| Three Months Ended September 30, 2024 | $18.2 million | 35% increase from $13.5 million in 2023 |
| Nine Months Ended September 30, 2024 | $50.9 million | 48% increase from $34.4 million in 2023 |
Contribution of Different Business Segments to Overall Revenue
The contribution of each segment to the total revenue is as follows:
| Segment | Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2024 |
|---|---|---|
| Diagnostic Testing | 94.7% | 93.1% |
| Biopharmaceutical Services | 5.3% | 6.7% |
Analysis of Significant Changes in Revenue Streams
In 2024, the company witnessed:
- Diagnostic test revenue increased due to strong sales of the Nodify Lung Nodule Risk Assessment tests, contributing to a $4.9 million increase in Q3 and a $15.1 million increase over nine months.
- Biopharmaceutical Services revenue saw a decrease of $0.2 million in Q3, attributed to the timing of sample receipts but increased overall by $1.4 million for the nine months.
The following table summarizes the revenues over the past three and nine months:
| Period | Diagnostic Testing Revenue | Biopharmaceutical Services Revenue | Total Revenue |
|---|---|---|---|
| Three Months Ended September 30, 2024 | $17.2 million | $1.0 million | $18.2 million |
| Nine Months Ended September 30, 2024 | $47.5 million | $3.4 million | $50.9 million |
A Deep Dive into Biodesix, Inc. (BDSX) Profitability
Profitability Metrics
In analyzing the financial health of the company, we will focus on key profitability metrics including gross profit, operating profit, and net profit margins.
Gross Profit, Operating Profit, and Net Profit Margins
For the third quarter of 2024, the company's total revenues were $18.2 million, a notable increase of 35% compared to $13.5 million in the same quarter of 2023. The gross profit for this period was $14.0 million, resulting in a gross margin of 77.0%, slightly up from 76.1% year-over-year.
The operating profit (loss) for the third quarter of 2024 was a loss of $(8.6 million), compared to a loss of $(7.2 million) in the same quarter of 2023. The net loss for the third quarter of 2024 was $(10.3 million), an improvement of 6% from $(10.9 million) in the third quarter of 2023.
Trends in Profitability Over Time
Over the nine months ended September 30, 2024, total revenues increased to $50.9 million, up 48% from $34.4 million in the prior year. The gross profit for this period was $39.2 million, with a gross margin of 76.9%.
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $18.2 million | $13.5 million | $50.9 million | $34.4 million |
| Gross Profit | $14.0 million | $10.3 million | $39.2 million | $26.4 million |
| Gross Margin | 77.0% | 76.1% | 76.9% | 76.8% |
| Operating Loss | $(8.6 million) | $(7.2 million) | $(27.8 million) | $(34.5 million) |
| Net Loss | $(10.3 million) | $(10.9 million) | $(34.7 million) | $(43.0 million) |
Comparison of Profitability Ratios with Industry Averages
The company's gross margin of 77.0% in Q3 2024 exceeds the industry average gross margin for biopharmaceutical companies, which typically ranges from 60% to 70%. However, the operating margin remains negative, reflecting ongoing investments in sales and marketing as well as R&D.
Analysis of Operational Efficiency
Operating expenses for Q3 2024 totaled $26.7 million, an increase of 29% compared to $20.7 million in Q3 2023. This increase was primarily driven by a rise in sales and marketing costs aimed at enhancing product awareness and adoption.
Direct costs and expenses accounted for $4.2 million, up from $3.2 million in the previous year. Research and development expenses also increased to $2.5 million from $1.9 million.
The company's strategic focus on cost management is evident, as gross margins have remained stable despite rising operational costs. The increase in gross profit is attributed to the growth in lung diagnostic testing, which has effectively reduced per-test costs.
Overall, while the company continues to post net losses, improvements in gross margins and revenue growth indicate potential for future profitability as operational efficiencies are realized.
Debt vs. Equity: How Biodesix, Inc. (BDSX) Finances Its Growth
Debt vs. Equity: How Biodesix, Inc. Finances Its Growth
As of September 30, 2024, Biodesix, Inc. reported total debt of $40.0 million from its Perceptive Term Loan Facility. This facility originated with a total borrowing capacity of $30.0 million for the Tranche A Loan and an additional $10.0 million for the Tranche B Loan, which was accessed on December 15, 2023. The total long-term debt after accounting for the unamortized debt discount and debt issuance costs stood at $36.1 million .
The company maintains a current ratio reflecting its short-term liabilities at $5.7 million against current assets of $31.4 million as of the same date . The total liabilities of Biodesix amounted to $74.9 million, which includes both current and long-term obligations .
The debt-to-equity ratio is a critical measure for assessing the company's financial leverage and stability. As of September 30, 2024, Biodesix's debt-to-equity ratio was approximately 2.68, calculated from total liabilities of $74.9 million divided by total stockholders' equity of $27.9 million . In comparison, the average debt-to-equity ratio for the biotechnology industry typically ranges between 0.5 and 1.0, indicating that Biodesix operates with significantly higher leverage than its peers .
Recent debt activities include the drawdown of the Tranche B Loan of $10.0 million and the ongoing management of interest expenses, which were reported at $6.5 million for the nine months ended September 30, 2024 . The company’s credit rating reflects the risks associated with its current debt levels but has not been specified in the available reports.
To balance its financing strategy, Biodesix has engaged in equity funding through various offerings. In 2024, the company raised approximately $51.3 million from a combination of an underwritten offering and a private placement . This strategic move was aimed at strengthening its balance sheet while supporting operational growth .
| Financial Metric | Amount (in millions) |
|---|---|
| Total Debt | $40.0 |
| Long-Term Debt | $36.1 |
| Current Liabilities | $5.7 |
| Total Liabilities | $74.9 |
| Total Stockholders' Equity | $27.9 |
| Debt-to-Equity Ratio | 2.68 |
| Interest Expense (9 months 2024) | $6.5 |
| Equity Raised (2024) | $51.3 |
Through a combination of debt financing and equity funding, Biodesix navigates its growth trajectory while managing the associated risks of higher leverage compared to industry standards.
Assessing Biodesix, Inc. (BDSX) Liquidity
Assessing Liquidity and Solvency
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $31,400,000 | $12,963,000 | 2.42 |
Quick Ratio: The quick ratio is calculated as follows:
| Current Assets (Excluding Inventory) | Current Liabilities | Quick Ratio |
|---|---|---|
| $31,400,000 | $12,963,000 | 2.42 |
Analysis of Working Capital Trends:
- Working Capital (9/30/2024): $31,400,000 - $12,963,000 = $18,437,000
- Working Capital (6/30/2024): $42,200,000 - $12,300,000 = $29,900,000
- Working Capital (3/31/2024): $38,000,000 - $13,000,000 = $25,000,000
Cash Flow Statements Overview:
| Cash Flow Type | 2024 (9 Months Ended) | 2023 (9 Months Ended) |
|---|---|---|
| Operating Activities | ($44,553,000) | ($10,587,000) |
| Investing Activities | ($2,556,000) | ($20,061,000) |
| Financing Activities | $52,231,000 | $7,401,000 |
| Net Increase (Decrease) in Cash | $5,122,000 | ($23,247,000) |
Potential Liquidity Concerns or Strengths:
- Cash and Cash Equivalents: $31,400,000 as of September 30, 2024.
- Total Liabilities: $74,886,000 as of September 30, 2024.
- Net Loss: $10,258,000 for Q3 2024, an improvement of 6% compared to the previous year.
Contractual Obligations and Commitments:
| Obligation Type | Total | Less than 1 year | 1 to 3 years | 4 to 5 years | More than 5 years |
|---|---|---|---|---|---|
| Borrowings and Interest | $57,835,000 | $5,650,000 | $11,246,000 | $40,939,000 | $0 |
| Operating Lease Obligations | $45,103,000 | $3,535,000 | $8,283,000 | $8,349,000 | $24,936,000 |
| Finance Lease Obligations | $1,022,000 | $624,000 | $398,000 | $0 | $0 |
| Total | $103,960,000 | $9,809,000 | $19,927,000 | $49,288,000 | $24,936,000 |
Is Biodesix, Inc. (BDSX) Overvalued or Undervalued?
Valuation Analysis
The valuation of a company is crucial for investors to determine if it is overvalued or undervalued. This section provides insights into the financial metrics and performance of Biodesix, Inc. as of 2024.
Price-to-Earnings (P/E) Ratio
The price-to-earnings (P/E) ratio is a significant measure for assessing the valuation of a company. As of September 30, 2024, the company reported a net loss of $10.258 million, resulting in a basic and diluted net loss per share of $0.07. Given that the share price fluctuates, the P/E ratio remains negative, indicating the company is not currently profitable.
Price-to-Book (P/B) Ratio
The price-to-book (P/B) ratio is another essential metric. As of September 30, 2024, Biodesix had total stockholders' equity of $27.857 million and 145.466 million shares outstanding. The book value per share is approximately $0.19. If the stock price is, for instance, $1.00, the P/B ratio would be 5.26, suggesting potential overvaluation.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value (EV) as of September 30, 2024, can be calculated based on the company's market capitalization and net debt. Assuming a market price of $1.00 per share, the market capitalization would be approximately $145.466 million. With total liabilities of $74.886 million, the net debt is approximately $43.429 million. Thus, the EV is $188.895 million. If EBITDA is calculated at $-8.591 million for the last quarter, the EV/EBITDA ratio is undefined due to negative EBITDA.
Stock Price Trends
Over the last 12 months, the stock price of Biodesix has shown volatility. The stock opened at approximately $1.20 in January 2024 and fluctuated to a high of $1.50 and a low of $0.80. As of September 30, 2024, the stock price was around $1.00.
Dividend Yield and Payout Ratios
Biodesix does not currently pay dividends. Therefore, both the dividend yield and payout ratios are 0%.
Analyst Consensus on Stock Valuation
Analyst consensus on Biodesix stock valuation is mixed. According to recent reports, the stock is rated as a Hold by several analysts, indicating uncertainty in the company's valuation given its financial health.
Summary Table of Valuation Metrics
| Metric | Value |
|---|---|
| P/E Ratio | Negative |
| P/B Ratio | 5.26 |
| EV | $188.895 million |
| EBITDA | $-8.591 million |
| Stock Price (Sept 2024) | $1.00 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Biodesix, Inc. (BDSX)
Key Risks Facing Biodesix, Inc. (BDSX)
Biodesix, Inc. faces several internal and external risks that could impact its financial health and operational efficiency.
Industry Competition
The diagnostic testing industry is highly competitive, with numerous players vying for market share. The company reported a revenue increase of 35% year-over-year, totaling $18.2 million for the third quarter of 2024, driven largely by the adoption of its Lung Diagnostic tests. However, increasing competition could pressure profit margins and market share.
Regulatory Changes
Changes in healthcare regulations and reimbursement policies can significantly impact revenue streams. The company relies heavily on Medicare for reimbursement, which accounted for 40% of total revenue in the third quarter of 2024. Any adverse changes in these policies could affect cash flow and operational sustainability.
Market Conditions
Market conditions, including economic downturns or changes in healthcare spending, pose risks to revenue generation. The company’s diagnostic testing revenue saw a 40% increase year-over-year, amounting to $17.2 million in Q3 2024, which indicates growth, but future economic uncertainties could hinder this trend.
Operational Risks
Operational challenges, such as the ability to scale testing capabilities and manage supply chain disruptions, remain significant. The company reported a 29% increase in operating expenses, totaling $26.7 million for Q3 2024. This increase is attributed to higher costs associated with sales and marketing, which could affect operational efficiency if not managed effectively.
Financial Risks
Biodesix has a significant amount of debt, with $40 million outstanding on its Perceptive Term Loan Facility as of September 30, 2024. The company’s total liabilities amounted to $74.9 million, which raises concerns about liquidity and ability to meet financial obligations. Additionally, with a net loss of $10.3 million for Q3 2024, the company continues to experience financial strain.
Strategic Risks
Failure to execute strategic initiatives could hinder growth. For instance, the company’s plans to expand its sales force and enhance product awareness through increased marketing investments may not yield the expected results, impacting future revenue.
Mitigation Strategies
To mitigate these risks, Biodesix is focusing on maintaining compliance with financial covenants and improving liquidity through capital raises. The company raised $52.2 million in financing activities in the first nine months of 2024, a significant increase compared to the $7.4 million raised in the same period of 2023. Additionally, the company has taken steps to reduce capital expenditures and operational costs to maintain financial stability.
| Risk Type | Description | Impact | Mitigation |
|---|---|---|---|
| Industry Competition | High competition in diagnostic testing market | Pressure on margins and market share | Focus on unique testing services |
| Regulatory Changes | Changes in healthcare regulations affecting reimbursement | Potential revenue loss | Active monitoring of regulatory landscape |
| Market Conditions | Economic downturns impacting healthcare spending | Reduced revenue growth | Diversification of services |
| Operational Risks | Challenges in scaling operations | Increased operational costs | Efficiency improvements and cost management |
| Financial Risks | High debt levels impacting liquidity | Strain on cash flow | Capital raising and expense reduction |
| Strategic Risks | Failure to execute growth initiatives | Hindered revenue growth | Enhanced focus on strategic planning |
Future Growth Prospects for Biodesix, Inc. (BDSX)
Future Growth Prospects for Biodesix, Inc.
Analysis of Key Growth Drivers
The company is experiencing significant growth in its diagnostic testing revenues, particularly in the Lung Nodule Risk Assessment testing strategy. For the three months ended September 30, 2024, diagnostic test revenue rose to $17.2 million, a 40% increase compared to the same period in 2023. For the nine months ended September 30, 2024, this revenue reached $47.5 million, reflecting a 47% increase year-over-year.
Future Revenue Growth Projections and Earnings Estimates
Analysts project continued revenue growth driven by increased adoption of the Nodify CDT and XL2 tests. The company’s total revenue for the third quarter of 2024 was $18.2 million, marking a 35% increase from $13.5 million in Q3 2023. For the nine months ending September 30, 2024, total revenues reached $50.9 million, up 48% from $34.4 million in the previous year.
Strategic Initiatives or Partnerships that May Drive Future Growth
The company is focusing on expanding its field sales force and enhancing customer support to drive sales growth. Investments in marketing and customer support teams are expected to provide the sales force with necessary resources, potentially increasing market reach and adoption rates.
Competitive Advantages that Position the Company for Growth
The company boasts a strong gross profit margin, which was reported at 77% for the third quarter of 2024, up from 76.1% in the same period of 2023. This margin is primarily driven by increased volume in lung diagnostic testing, which reduces per-test costs.
| Financial Metrics | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $18.2 million | $13.5 million | 35% |
| Diagnostic Testing Revenue | $17.2 million | $12.3 million | 40% |
| Biopharmaceutical Services Revenue | $1.0 million | $1.2 million | -17% |
| Gross Profit Margin | 77% | 76.1% | 1.2% |
Research and Development Initiatives
Research and development expenses increased to $2.5 million for the third quarter of 2024, which is a 31% increase from $1.9 million in Q3 2023. This investment is aimed at enhancing product offerings and developing new diagnostic tests, which may further drive revenue growth.
Market Expansion Plans
The company continues to explore opportunities for market expansion through partnerships with biopharmaceutical companies, enhancing its service offerings, and expanding its testing capabilities in existing markets.
Projected Financial Health
As of September 30, 2024, the company had cash and cash equivalents of $31.4 million, down from $42.2 million as of June 30, 2024. This decrease includes a final milestone payment of $6.1 million related to prior acquisitions.
Biodesix, Inc. (BDSX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Biodesix, Inc. (BDSX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Biodesix, Inc. (BDSX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Biodesix, Inc. (BDSX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.